- Email: [email protected]
Hormone replacement therapy and survival after surgery for ovarian cancer
Citutiutw
Neuroophthalmologic
Digre KB: Varner Dqwtment
uf Ohsterrics
School of’ Madicine. 84132.
effects of intravenous magnesium sulfate
M.W; Schiffman
JS
uncl Gvnccology.
50 North
Mdicul
Uniwrsi/~~
Dr., Suit Luke
of Uruh Ci/y.
UT
USA
AM J OBSTET GYNECOL 1990 16316 I (1848-1852) To test the hypothesis that visual disturbances are more common during intravenous magnesium sulfate administration than at I to 4 days after discontinuation of the drug. I3 women underwent bedside neuroophthalmologic examinations during intravenous magnesium sulfate tocolysis at 2.0 to 3.0 gm/hr and again at I to 4 days after cessation of therapy. Visual symptoms were common during intravenous magnesium sulfate administration. Blurred vision was present in 12 of 13 patients and diplopia was present in IO of 13 patients. Abnormal findings during neuroophthalmologic examination occurred in all patients during intravenous magnesium sulfate administration. Findings included ptosis. accommodative and convergence insufficiency. and abnormal pupillary responsiveness to light and near. All patients were symptom-free and had normal examinations after magnesium sulfate was discontinued. These tindings suggest that visual disturbances with therapeutic magnesium sulfate are
ONCOLOGY Hormone r-t
therapy and survival after surgery for ovarian
cancer
Eeles RA; Tan S: Wiltshaw E; Fryatt JH; Harmer CL; Blake PR; Chilvers Dqxwtmcni
of Mdicitw.
I; A’Hern CED
Ruyul Mursclcn
Huspitul.
RP: Shepherd London
S W3
6JJ. GBR
BR MED J 1991 302/6771 (259-262) Objective - To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salpingooophorectomy because of epithelial ovarian cancer. Design -
)wni
Ihr Litcrutuw
The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to I .20). In addition. there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90: 95% confidence interval 0.52 to I .54). Conclusions - This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial. Infertility-associated
endometrial
cancer risk may be limited to
specific subgroups of infertile women
Escobedo
LG: Lee NC: Peterson
Division
of Rqwuductivc
Preventiun Atluntu.
und Hrulrh GA,
Htwlth. Promotion.
HB: Wingo Center ,ftir
PA Chronic
Diwuw
Centers ,fvr Di.wu.w
Cunrrol.
USA
OBSTET GYNECOL 1991 77/l (124-128) Data from previous studies suggest that infertility is a risk factor for endometrial cancer. We used data from the Cancer and Steroid Hormone Study to further characterize this relationship. The subject group comprised 399 women ages 20-54 with newly diagnosed epithelial endometrial cancer ascertained through six cancer registries. The control group comprised 3040 women in the same age range selected by random-digit telephone dialing from the same geographic areas where cancer patients resided. Compared with women who reported no fertility problem. women with physician-diagnosed infertility who had reported at least cancer. Women had an
2 years of infertility had an odds ratio for endometrial adjusted for age. of I .7 (95% confidence interval I. l-2.6). who reported infertility resulting from ovarian factors adjusted odds ratio of 4.2 (95% confidence interval
I .7-10.4). These results suggest that factors such as anovulation may explain much of the increased risk of endometrial cancer found among subgroups of infertile women. Establishment
and characterization
of a cell line (OMC-3)
Retrospective analysis by review of patients’ notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after
originating from a human mutinous cystadenocarcinoma
diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. Setting - Gynaecological oncology unit of Royal
legs. 2-7 Duiguku-cho.
Marsden Hospital. Patients - 373 Patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingo-oophorectomy for epithelial ovarian cancer. In all. 78 had received hormone replacement therapy starting at a median of four months after diagnosis. Intervention - A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. Main outcome measures - Overall survival and disease free survival. Results - There WiiS no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer. differentiation of tumour, histological results. and time to relapse).
349
of the
ovary
Yamada Dqxwtment
T: Ueda M; Otsuki uf Ohsterrics
Y; Ueki M; Sugimoto
und Gynrcolugy, Tukulsuki.
Osuku
0
Mrdicul
Coi-
Osuku 569. JPN
GYNECOL ONCOL 1991 40/2 (I 18-128) A new human ovarian carcinoma cell line, designated
OMC-3.
was established from the mutinous cystddenocarcinoma of a 59-year-old woman. This cell line has grown well for 65 months and has been subcultured more than 50 times. Monolayercultured cells are polygonal in shape. showing a pavement-like arrangement and a tendency to pile up without contact inhibition. The chromosomal number shows aneuploidy and the modal chromosomal number is in the hypodiploid range. The cells were transplanted into the subcutis of nude mice and produced tumors resembling the original tumor. Ten thousand OMC-3 cells produced CA-125 (228-580 U) and CA-19-9 (2900-5640 U) during 17 days in culture media. CA-125 and CA-19-9 were demonstrated immunohistochemically in the original tumor. heterotransplanted tumor. and OMC-3 cells. The cells contain no estrogen or progesterone receptors. OMC-3 cells were sen-
Neuroophthalmologic
Digre KB: Varner Dqwtment
uf Ohsterrics
School of’ Madicine. 84132.
effects of intravenous magnesium sulfate
M.W; Schiffman
JS
uncl Gvnccology.
50 North
Mdicul
Uniwrsi/~~
Dr., Suit Luke
of Uruh Ci/y.
UT
USA
AM J OBSTET GYNECOL 1990 16316 I (1848-1852) To test the hypothesis that visual disturbances are more common during intravenous magnesium sulfate administration than at I to 4 days after discontinuation of the drug. I3 women underwent bedside neuroophthalmologic examinations during intravenous magnesium sulfate tocolysis at 2.0 to 3.0 gm/hr and again at I to 4 days after cessation of therapy. Visual symptoms were common during intravenous magnesium sulfate administration. Blurred vision was present in 12 of 13 patients and diplopia was present in IO of 13 patients. Abnormal findings during neuroophthalmologic examination occurred in all patients during intravenous magnesium sulfate administration. Findings included ptosis. accommodative and convergence insufficiency. and abnormal pupillary responsiveness to light and near. All patients were symptom-free and had normal examinations after magnesium sulfate was discontinued. These tindings suggest that visual disturbances with therapeutic magnesium sulfate are
ONCOLOGY Hormone r-t
therapy and survival after surgery for ovarian
cancer
Eeles RA; Tan S: Wiltshaw E; Fryatt JH; Harmer CL; Blake PR; Chilvers Dqxwtmcni
of Mdicitw.
I; A’Hern CED
Ruyul Mursclcn
Huspitul.
RP: Shepherd London
S W3
6JJ. GBR
BR MED J 1991 302/6771 (259-262) Objective - To evaluate whether hormone replacement therapy affects survival in women who have undergone bilateral salpingooophorectomy because of epithelial ovarian cancer. Design -
)wni
Ihr Litcrutuw
The relative risk of dying in those who received hormone replacement therapy was 0.73 (95% confidence interval 0.44 to I .20). In addition. there was no significant difference in disease free survival (relative risk in those receiving hormone replacement therapy was 0.90: 95% confidence interval 0.52 to I .54). Conclusions - This study shows that hormone replacement therapy is unlikely to have a detrimental effect on the prognosis of patients with ovarian cancer, but this would be shown conclusively only by a randomised controlled trial. Infertility-associated
endometrial
cancer risk may be limited to
specific subgroups of infertile women
Escobedo
LG: Lee NC: Peterson
Division
of Rqwuductivc
Preventiun Atluntu.
und Hrulrh GA,
Htwlth. Promotion.
HB: Wingo Center ,ftir
PA Chronic
Diwuw
Centers ,fvr Di.wu.w
Cunrrol.
USA
OBSTET GYNECOL 1991 77/l (124-128) Data from previous studies suggest that infertility is a risk factor for endometrial cancer. We used data from the Cancer and Steroid Hormone Study to further characterize this relationship. The subject group comprised 399 women ages 20-54 with newly diagnosed epithelial endometrial cancer ascertained through six cancer registries. The control group comprised 3040 women in the same age range selected by random-digit telephone dialing from the same geographic areas where cancer patients resided. Compared with women who reported no fertility problem. women with physician-diagnosed infertility who had reported at least cancer. Women had an
2 years of infertility had an odds ratio for endometrial adjusted for age. of I .7 (95% confidence interval I. l-2.6). who reported infertility resulting from ovarian factors adjusted odds ratio of 4.2 (95% confidence interval
I .7-10.4). These results suggest that factors such as anovulation may explain much of the increased risk of endometrial cancer found among subgroups of infertile women. Establishment
and characterization
of a cell line (OMC-3)
Retrospective analysis by review of patients’ notes and questionnaires completed by general practitioners to compare the overall survival and disease free survival in patients with ovarian cancer who did or did not receive hormone replacement therapy after
originating from a human mutinous cystadenocarcinoma
diagnosis. Data were analysed by Cox regression, with hormone replacement therapy as a time dependent covariate because patients who received hormone replacement did so at different times after diagnosis. Setting - Gynaecological oncology unit of Royal
legs. 2-7 Duiguku-cho.
Marsden Hospital. Patients - 373 Patients aged 50 years or younger who attended the hospital from 1972 to 1988. All of the women had undergone bilateral salpingo-oophorectomy for epithelial ovarian cancer. In all. 78 had received hormone replacement therapy starting at a median of four months after diagnosis. Intervention - A questionnaire was sent to the general practitioners of all patients who were not recorded as having received hormone replacement therapy. Main outcome measures - Overall survival and disease free survival. Results - There WiiS no significant difference in survival between women receiving hormone replacement therapy and those not receiving it after accounting for the effects of other known prognostic factors (stage of cancer. differentiation of tumour, histological results. and time to relapse).
349
of the
ovary
Yamada Dqxwtment
T: Ueda M; Otsuki uf Ohsterrics
Y; Ueki M; Sugimoto
und Gynrcolugy, Tukulsuki.
Osuku
0
Mrdicul
Coi-
Osuku 569. JPN
GYNECOL ONCOL 1991 40/2 (I 18-128) A new human ovarian carcinoma cell line, designated
OMC-3.
was established from the mutinous cystddenocarcinoma of a 59-year-old woman. This cell line has grown well for 65 months and has been subcultured more than 50 times. Monolayercultured cells are polygonal in shape. showing a pavement-like arrangement and a tendency to pile up without contact inhibition. The chromosomal number shows aneuploidy and the modal chromosomal number is in the hypodiploid range. The cells were transplanted into the subcutis of nude mice and produced tumors resembling the original tumor. Ten thousand OMC-3 cells produced CA-125 (228-580 U) and CA-19-9 (2900-5640 U) during 17 days in culture media. CA-125 and CA-19-9 were demonstrated immunohistochemically in the original tumor. heterotransplanted tumor. and OMC-3 cells. The cells contain no estrogen or progesterone receptors. OMC-3 cells were sen-